Clinical trial readout dates for Amylyx Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 Avexitide Post Bariatric Hypoglycemia · NCT06747468 | July 2026 Primary data collected |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 3 Avexitide (Exendin 9-39) Post-Bariatric Hypoglycemia (PBH) | January 30, 2019 Enrollment Conclusion |
Amylyx Pharmaceuticals Inc. reported $768M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $45M; at that rate the cash would last about 17 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |